TruSight Oncology portfolio enables clinical research and in-vitro diagnostic CGP solutions ...

Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead asset, nizubaglustat, will feature ...

Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025.

Rhythm Pharmaceuticals (RYTM) announced the presentation of new, real-world data that showed four pediatric patients with acquired ...

Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical ...